UM171 saves another life

ExCellThera’s presentation at Meeting on the Mesa 2019 (video)

Molécule pour traiter des patients atteints de leucémie aigüe

ExCellThera’s safer allogeneic transplants

La recherche à l’IRIC : les travaux de Guy Sauvageau

Dalton Pharma Services enters into a drug development and manufacturing services agreement with ExCellThera Inc.

ExCellThera Founder and CEO, Guy Sauvageau, elected member of the Academy of Science, Royal Society of Canada

Canadian cord-blood procedure passes key milestone in cancer trial

Cancer: une molécule québécoise aux résultats «extraordinaires»

Start-ups – Des jeunes pousses déjà grandes